Drug therapy of renal cell carcinoma
- VernacularTitle:肾癌的药物治疗
- Author:
Mafei KANG
- Publication Type:Journal Article
- Keywords:
Kidney neoplasms;
Drug therapy;
Chemotherapy;
Immunotherapy
- From:
Journal of International Oncology
2008;35(6):464-466
- CountryChina
- Language:Chinese
-
Abstract:
Immunochemotherapy is still the primary drug therapy of renal cell carcinoma(RCC), and chemotherapy is effective too. The combination of gemcitabine and cisplatin is the standard regimen now. How-ever, emerge of targeted therapeutic agents has altered the treatment of RCC. Multitargeted tyrosine kinase in-hibitor, such as sunitinib and sorafenib, and mammalian target of rapamycin (roTOR) inhibitors( temsiroll-mus), and anti-tumor monoclonal antibody, such as bevacizumab, have already become the first line election.
